Pfenex is an innovative, leading-edge company with a core focus on bringing high-quality biosimilars to market in a cost-effective way.

We are one of the only companies focused on non-glycosylated biosimilars, creating a differentiated platform approach and competitive advantage. This focus allows us to ensure a robust pipeline of high-quality therapeutics.

Our unique protein production platform and world-class bioanalytic approach enables the potential for a fingerprint-like identity to a reference drug.

Our partnership with Hospira on our lead product – PF582, a biosimilar to Lucentis (ranibizumab) – validates our approach to increase access to lower-cost, high-quality biologic drugs.

products zoom